XML 78 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisition (Tables)
12 Months Ended
Nov. 30, 2019
Business Combinations [Abstract]  
Summary of Fair Value of Consideration
The following summarizes the fair value of the consideration of the Acquisition as of the purchase date:
 
Consideration
    
Cash
  $10,500,000 
Cryo-Cell common stock
   3,500,000 
Cord blood inventory earnout
   4,698,255 
  
 
 
 
Consideration
  $18,698,255 
  
 
 
 
Summary of Preliminary Allocation of Total Purchase Price
The following summarizes the allocation of the total purchase price for the Acquisition:
 
Accounts receivable
  $188,019 
Inventory
   16,037,957 
Prepaid expenses
   68,867 
Property and equipment
   568,407 
Other asset—Tianhe capital stock
   308,000 
Brand
   31,000 
Customer relationships
   960,000 
  
 
 
 
Total identifiable net assets acquired
   18,162,250 
  
 
 
 
Less: Deferred revenue
   (1,405,406
  
 
 
 
Goodwill
   1,941,411 
  
 
 
 
Total
  $18,698,255 
  
 
 
 
Schedule of Unaudited Pro Forma Results
The following table provides the Company’s consolidated unaudited pro forma revenues, net income per basic and diluted common share had the results of the acquired businesses’ operations been included in its operations commencing on December 1, 2016, based on available information related to the respective operations. This proforma information presented is not necessarily indicative either of the combined results of operations that actually would have been realized by the Company had the acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results, and does not account for any operation improvements to be made by the Company post-acquisition.
 
   Twelve months ended
November 30, 2018
 
Revenue
  $31,388,278 
Net income (loss)
  ($2,658,679
Earnings (loss) per share:
  
Basic
  ($0.36
Diluted
  ($0.36